Bmi-1 is related to proliferation, survival and poor prognosis in pancreatic cancer

Cancer Science

Volumn 101, Issue 7, 2010, Pages 1754-1760

  Song, Wenjie ^a   Tao, Kaishan ^a   Li, Haimin ^a   Jin, Chen ^a   Song, Zhenshun ^a   Li, Jun ^a   Shi, Hai ^a   Li, Xiao ^a   Dang, Zheng ^a   Dou, Kefeng ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BMI1 PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; SHORT HAIRPIN RNA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LENTIVIRINAE; LYMPH NODE METASTASIS; MALE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; SURVIVAL RATE; UPREGULATION;

AGED; BLOTTING, WESTERN; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; SURVIVAL RATE;

EID: 77954631291     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01577.x     Document Type: Article

References (44)

1. Wang L, Yang GH, Lu XH, Huang ZJ, Li H. Pancreatic cancer mortality in China (1991-2000). World J Gastroenterol 2003, 9:1819-23.
2. Guo X, Cui Z. Current diagnosis and treatment of pancreatic cancer in China. Pancreas 2005, 31:13-22.
3. Jimeno A, Feldmann G, Suarez-Gauthier A. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther 2009, 8:310-4.
4. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002, 2:897-909.
5. Jemal A, Siegel R, Ward E. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
6. Haupt Y, Alexander WS, Barri G, Klinken SP, Adams JM. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lympho-magenesis in E mu-myc transgenic mice. Cell 1991, 65:753-63.
7. van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Gulden H, Berns A. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 1991, 65:737-52.
8. Jacobs JJ, van Lohuizen M. Polycomb repression: from cellular memory to cellular proliferation and cancer. Biochim Biophys Acta 2002, 1602:151-61.
9. Park IK, Qian D, Kiel M. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 2003, 423:302-5.
10. Pardal R, Molofsky AV, He S, Morrison SJ. Stem cell self-renewal and cancer cell proliferation are regulated by common networks that balance the activation of proto-oncogenes and tumor suppressors. Cold Spring Harb Symp Quant Biol 2005, 70:177-85.
11. Park IK, Morrison SJ, Clarke MF. Bmi1, stem cells, and senescence regulation. J Clin Invest 2004, 113:175-9.
12. Lee K, Adhikary G, Balasubramanian S. Expression of Bmi-1 in epidermis enhances cell survival by altering cell cycle regulatory protein expression and inhibiting apoptosis. J Invest Dermatol 2008, 128:9-17.
13. Pasini D, Bracken AP, Helin K. Polycomb group proteins in cell cycle progression and cancer. Cell Cycle 2004, 3:396-400.
14. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 2006, 6:846-56.
15. Chiba T, Zheng YW, Kita K. Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. Gastroenterology 2007, 133:937-50.
16. Datta S, Hoenerhoff MJ, Bommi P. Bmi-1 cooperates with H-Ras to transform human mammary epithelial cells via dysregulation of multiple growth-regulatory pathways. Cancer Res 2007, 67:10286-95.
17. Wang Q, Li WL, You P. Oncoprotein BMI-1 induces the malignant transformation of HaCaT cells. J Cell Biochem 2009, 106:16-24.
18. Jacobs JJ, Scheijen B, Voncken JW, Kieboom K, Berns A, van Lohuizen M. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev 1999, 13:2678-90.
19. Liu L, Andrews LG, Tollefsbol TO. Loss of the human polycomb group protein BMI1 promotes cancer-specific cell death. Oncogene 2006, 25:4370-5.
20. Alajez NM, Shi W, Hui AB. Targeted depletion of BMI1 sensitizes tumor cells to P53-mediated apoptosis in response to radiation therapy. Cell Death Differ 2009, 16:1469-79.
21. Song LB, Zeng MS, Liao WT. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 2006, 66:6225-32.
22. Yonemitsu Y, Imazeki F, Chiba T. Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma. Hum Pathol 2009, 40:1304-11.
23. Sawa M, Yamamoto K, Yokozawa T. BMI-1 is highly expressed in M0-subtype acute myeloid leukemia. Int J Hematol 2005, 82:42-7.
24. Bea S, Tort F, Pinyol M. BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 2001, 61:2409-12.
25. Kim JH, Yoon SY, Jeong SH. Overexpression of Bmi-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer. Breast 2004, 13:383-8.
26. Kim JH, Yoon SY, Kim CN. The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett 2004, 203:217-24.
27. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005, 115:1503-21.
28. Tateishi K, Ohta M, Kanai F. Dysregulated expression of stem cell factor Bmi1 in precancerous lesions of the gastrointestinal tract. Clin Cancer Res 2006, 12:6960-6.
29. Martinez-Romero C, Rooman I, Skoudy A. The epigenetic regulators Bmi1 and Ring1B are differentially regulated in pancreatitis and pancreatic ductal adenocarcinoma. J Pathol 2009, 219:205-13.
30. Song W, Li H, Tao K. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract 2008, 62:1212-8.
31. Campani D, Esposito I, Boggi U. Bcl-2 expression in pancreas development and pancreatic cancer progression. J Pathol 2001, 194:444-50.
32. Wang Z, Song W, Aboukameel A. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer. Int J Cancer 2008, 123:958-66.
33. Wang Z, Azmi AS, Ahmad A. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathway. Cancer Res 2009, 69:2757-65.
34. Liu JH, Song LB, Zhang X. Bmi-1 expression predicts prognosis for patients with gastric carcinoma. J Surg Oncol 2008, 97:267-72.
35. Zhang XW, Sheng YP, Li Q. BMI1 and Mel-18 oppositely regulate carcinogenesis and progression of gastric cancer. Mol Cancer 2010, doi:10.1186/1476-4598-9-4.
36. Al-Aynati MM, Radulovich N, Ho J, Tsao MS. Overexpression of G1-S cyclins and cyclin-dependent kinases during multistage human pancreatic duct cell carcinogenesis. Clin Cancer Res 2004, 10:6598-605.
37. Aprelikova O, Xiong Y, Liu ET. Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase. J Biol Chem 1995, 270:18195-7.
38. Qin L, Zhang X, Zhang L. Downregulation of BMI-1 enhances 5-fluorouracil-induced apoptosis in nasopharyngeal carcinoma cells. Biochem Biophys Res Commun 2008, 371:531-5.
39. Lee JY, Jang KS, Shin DH. Mel-18 negatively regulates INK4a/ARF-independent cell cycle progression via Akt inactivation in breast cancer. Cancer Res 2008, 68:4201-9.
40. Li J, Gong LY, Song LB. Oncoprotein bmi-1 renders apoptotic resistance to glioma cells through activation of the ikk-nuclear factor-{kappa}rcub;b pathway. Am J Pathol 2009, 176:699-709.
41. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007, 26:1324-37.
42. Robertson KD, Jones PA. Tissue-specific alternative splicing in the human INK4a/ARF cell cycle regulatory locus. Oncogene 1999, 18:3810-20.
43. Chen F, Li Y, Lu Z, Gao J, Chen J. Adenovirus-mediated Ink4a/ARF gene transfer significantly suppressed the growth of pancreatic carcinoma cells. Cancer Biol Ther 2005, 4:1348-54.
44. Mohiuddin M, Chendil D, Dey S. Influence of p53 status on radiation and 5-flourouracil synergy in pancreatic cancer cells. Anticancer Res 2002, 22:825-30.